Women’s excess unhealthy life years: disentangling the unhealthy life years gap by Nusselder, Wilma J. et al.
HAL Id: hal-02265207
https://hal.archives-ouvertes.fr/hal-02265207
Submitted on 8 Aug 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Women’s excess unhealthy life years: disentangling the
unhealthy life years gap
Wilma J. Nusselder, Emmanuelle Cambois, Dagmar Wapperom, France
Meslé, Caspar Looman, Renata T.C. Yokota, Herman van Oyen, Carol
Jagger, Jean-Marie Robine
To cite this version:
Wilma J. Nusselder, Emmanuelle Cambois, Dagmar Wapperom, France Meslé, Caspar Looman, et
al.. Women’s excess unhealthy life years: disentangling the unhealthy life years gap. European
Journal of Public Health, Oxford University Press (OUP): Policy B - Oxford Open Option D, In
press, ￿10.1093/eurpub/ckz114￿. ￿hal-02265207￿
European Journal of Public Health, Vol. 0, No. 0, 1–5
 The Author(s) 2019. Published by Oxford University Press on behalf of the European Public Health Association.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
doi:10.1093/eurpub/ckz114
. .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . .
Women’s excess unhealthy life years: disentangling
the unhealthy life years gap
Wilma J. Nusselder1, Emmanuelle M. Cambois2, Dagmar Wapperom1, France Mesle´2,
Caspar W.N. Looman 1,Renata T.C. Yokota3,4, Herman Van Oyen3,5, Carrol Jagger6,7,
Jean Marie Robine8,9
1 Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands
2 INED (French Institute for Demographic Studies), Mortality, Health, Epidemiology Research Unit, Paris, France
3 SD Epidemiology and Public Health, Sciensano, Brussels, Belgium
4 Department of Sociology, Interface Demography, Vrije Universiteit Brussel, Brussels, Belgium
5 Department of Public Health and Primary Care, Ghent University, Ghent, Belgium
6 Instiute of Health and Society, Newcastle University, Newcastle upon Tyne, UK
7 Newcastle University Institute for Ageing, Newcastle upon Tyne, UK
8 Inserm (French Institute of Health and Medical Research), CERMES3 Research Unit, Paris, France
9 EPHE (E´cole Pratique des Hautes E´tudes), MMDN Research Unit, Univ., Montpellier, France
Correspondence: Wilma J. Nusselder, Department of Public Health, Erasmus MC, P.O.Box 2040, 3000 CA Rotterdam, the
Netherlands, Tel: +31 107038454, Fax: +31 108475, e-mail: w.nusselder@erasmusmc.nl
Background: Compared to men, women live longer but have more years with disability. We assessed the contri-
bution of gender differences in mortality and disability, total and by cause, to women’s excess unhealthy life years
(ULYs).Methods:We used mortality data for France 2008 from Eurostat, causes of death from the Ce´piDc-INSERM-
database; and disability and chronic conditions data from the French Disability Health Survey 2008–09. ULYs were
calculated by the Sullivan method. The contributions of mortality and disability differences to gender differences
in ULY were based on decomposition analyses. Results: Life expectancy of French women aged 50 was 36.3 years of
which 19.0 were ULYs; life expectancy of men was 30.4 years of which 14.2 were ULYs. Of the 4.8 excess ULYs in
women, 4.0 years were due to lower mortality. Of these 4.0 ULYs, 1.8 ULY originated from women’s lower
mortality from cancer, 0.8 ULY from heart disease and 0.3 ULY from accidents. The remaining 0.8 excess ULY in
women were from higher disability prevalence, including higher disability from musculoskeletal diseases (+1.8
ULY) and anxiety-depression (+0.6 ULY) partly offset by lower disability from heart diseases (0.8 ULY) and
accidents (0.3 ULY). Conclusion: Lower mortality and higher disability prevalence contributed to women’s
longer life expectancy with disability. Women’s higher disability prevalence due to non-fatal disabling
conditions was partly offset by lower disability from heart disease and accidents. Conditions differentially
impact gender differences in ULY, depending on whether they are mainly life-threatening or disabling.
The conclusions confirm the health-survival paradox.
. .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . .
Introduction
Women experience lower mortality, but report more disabilitycompared to men of the same age. The female longevity
advantage and the ‘health-survival paradox’ have received much
attention in the scientific literature, but the fact that this implies
that women live many more years with disability has received scant
attention.1–4 In general, the focus of past research has been on total life
expectancy and on healthy life expectancy, in Europe measured with
the healthy life years (HLYs).5 Gender differences in HLY are generally
much smaller than in life expectancy owing to opposite gender dif-
ferences in mortality and disability which reduce the gap in HLY. In
some countries, women have fewer HLYs than men indicating that
their mortality advantage is offset by their disability disadvantage.
However, the same opposing gender differences increase the gender
gap in unhealthy life years (ULYs)2,3,6 and gender differences in ULY
may even be larger than gender differences in life expectancy.3
Insight into the gender gap in ULY and the role of differences in
mortality and disability, both in general and from specific chronic
conditions, is relevant to better understand gender disparities and to
optimize strategies to reduce these inequalities. A high contribution of
a specific disease may point to specific risk factors, possibly modifiable.
The aim of this study is to improve understanding of gender
disparities in ULY by quantifying the contribution of mortality
and disability differences to the origin of gender gap in ULYs,
both in total and from different causes of death and disability. We
will address the following questions: (i) what is the contribution of
women’s lower mortality (extending the time at risk of disability)
and higher prevalence of disability to the gender gap in ULY and (ii)
which causes of death and disability contribute most to this gender
difference. We focus on France, given the availability of a large
survey that comprises both the household and institutional
population and includes a large set of conditions, including several
mental disorders lacking in most previous studies.
Methods
Data
Table 1 presents the proportional mortality and disability for each
disease group.
Deaths and population by age and gender for the year 2008 for
France from Eurostat were derived from the Eurohex website.7
Mortality and disability data by cause are presented in table 1.
Mortality data by underlying cause of death were obtained from the
Ce´piDc-INSERM-database.8
Data on disability by cause were derived in a previous paper9 based
on the French Disability Health Survey (‘Enqueˆte Handicap et Sante´’)
2008–09 which consists of a survey among persons living in private
households, HSM and a survey among persons living in in people
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living in nursing homes, homes for the elderly and mental institutions.
Further details of the Disability Health Survey 2008–09 can be found
elsewhere.10,11 Disability prevalence by cause was derived using the at-
tribution method based on the additive hazard model.1,12 This method
takes into account multi-morbidity and that people without reported
diseases can still report disability. Further details on the method to
estimate disability by cause are given in the Supplementary material.
Definition of disability
To define disability we used the Global Activity Limitation Indicator
(GALI), which is used to calculate HLY across Europe for health
monitoring and target setting.5,13 The GALI is a single question ‘For
at least the last 6 months, have you been limited because of a health
problem in activities people usually do?’ aiming to capture long-
term limitation (>6 months), and with three severity levels: none,
limited but not severely and severely limited. The reliability and
validity of the GALI have already been reported.14–19 People were
considered to be disabled (unhealthy) when they reported any
limitation. This is the cut-off used in the HLY measure in Europe.
Causes of disability
We included the following groups of chronic conditions as causes of
disability: heart diseases, cerebrovascular accident, peripheral vascular
disease (PVD), cancer, chronic non-specific lung diseases (CNSLD),
musculoskeletal diseases, Alzheimer’s and Parkinson’s disease, other
neurological diseases (multiple sclerosis, and other unspecific neuro-
logical problems), depression and anxiety, other mental diseases
(autism, schizophrenia and other unspecified psychiatric impair-
ments), diabetes mellitus and accidents. These causes were selected
considering the availability of diseases in the survey and main
disability causes in prior research.6,20,21 Supplementary table S1
presents the disease groups and diseases within each group.
Cause of death
We grouped causes of death similarly to the standard groupings for
causes of death, however because not all diseases that are disabling
are fatal (and vice-versa) we made some adjustments. For complete-
ness we included causes of death that do not cause long-term
disability or were not distinguished in the disability survey, such
as acute respiratory infections and other circulatory diseases.
Causes of disability that are not common causes of death, such as
musculoskeletal disorders, are included in the cause of death classi-
fication, but with virtually absent mortality.
Life table and decomposition methods
Life expectancy with GALI disability, i.e. ULYs at age 50 for men and
women were estimated by the Sullivan method. This method uses
the gender-specific prevalence of disability in each age group to
divide the number of person-years years in the standard life table
into years with and without disability.16,22
The contribution of specific conditions to gender difference in
ULYs was estimated by a life table decomposition tool which
partitions the difference in ULYs into additive contributions of
causes.1 The decomposition analysis assessed the difference in ULY
because of smaller (higher) total mortality rates and/or disability
prevalence (by age) from a given cause, in women relative to men.
First, the difference in the number of unhealthy person-years (by
age) was decomposed into two parts: the first part reflecting the
smaller (larger) number of person-years (‘mortality effect’) and
the second part reflecting the smaller (higher) prevalence of
disability (‘disability effect’). Second, the mortality and disability
effects were decomposed by age. For mortality, the decomposition
method distinguishes between the age of origin (i.e. the age
where mortality differences originate) and the age at destination
(i.e. age groups to which person-years are added or removed). For
decomposition by age, the age at origin is used,1 which gives the
same result as the decomposition method of Andreev et al.23 Third,
each age effect was decomposed by cause (disease contribution). The
decomposition tool in R, including the decomposition by age, is
provided in the Supplementary material. The decomposition
analyses also output the decomposition of HLY, which is
presented as Supplementary material (Supplementary table S2) for
comparison.
Table 1 Mortality and disability by disease group, age group and sex, France, 2008 based on Ce´piDc-INSERM-database8 and Disability Health
Survey9
Deaths by cause, % of total Disability by cause, % of total
Men Women Men Women
50–64 65–84 85+ 50–64 65–84 85+ 50–64 65–84 85+ 50–64 65–84 85+
Heart disease 12.4 16.5 23.6 7.4 8.7 11.1 9.9 14.8 15.4 4.9 8.9 9.6
CVA 2.8 5.3 7.0 3.3 3.7 5.0 1.6 3.9 4.1 1.0 1.9 2.3
PVD 0.3 0.6 0.8 0.1 0.1 0.2 2.5 3.4 2.7 1.0 1.1 1.3
Other CVD 2.1 2.9 3.7 1.6 1.7 2.1 n.a. n.a. n.a. n.a. n.a. n.a.
Musculoskeletal 0.3 0.5 0.7 0.6 0.6 0.8 28.3 21.1 15.5 38.9 33.5 19.9
Cancer 50.3 44.9 25.9 57.6 57.0 51.8 3.1 5.4 2.7 5.2 4.5 2.6
Alzheimer/Parkinson 0.4 3.3 8.3 0.7 1.3 2.7 1.0 2.3 7.3 1.0 3.0 7.5
Other neurological 2.0 1.6 0.9 3.0 2.9 2.6 2.4 1.3 2.2 2.1 1.6 0.9
CNSLD 1.3 2.3 3.0 0.9 1.1 1.4 6.4 6.1 6.3 4.4 3.7 2.4
Acute respiratory infec. 0.9 1.7 4.0 0.7 0.8 1.1 n.a. n.a. n.a. n.a. n.a. n.a.
Anxiety and depression 0.2 0.1 0.3 0.3 0.3 0.3 6.5 3.6 3.2 10.8 8.2 4.7
Other mental diseases 3.1 0.8 0.3 1.8 1.5 0.9 1.7 0.9 0.8 0.7 0.4 0.7
Diabetes mellitus 1.6 2.5 2.3 1.6 2.0 2.6 3.1 3.2 1.9 4.0 4.8 2.8
Accidents 12.7 11.8 14.0 12.1 11.7 11.8 6.3 3.8 1.9 2.1 1.9 1.4
Other/background 9.5 5.2 5.3 8.4 6.6 5.3 27.4 29.9 36.1 23.9 26.3 43.7
Total 100 100 100 100 100 100 100 100 100 100 100 100
Note: CVA = cerebrovascular accident (cerebrovascular disease according to ICD-10 terminology). PVD = peripheral vascular disease. Other
CVD = other cardiovascular diseases. CNSLD = chronic non-specific lung disease. Alzheimer’s/Parkinson groups include dementia. Anxiety
and depression are mood disorders. n.a. = not distinguished as separate cause of disability.
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Results
Life expectancy of women aged 50 was 36.3 (95% CI 36.3–36.4)
years and of men 30.4 years (95% CI 30.4–30.4) (table 2). Life
expectancy with GALI disability was 19.0 years (95% CI: 18.4–
19.6) for women compared to 14.2 years (95% CI 13.6–14.8) for
men. The gender gap in total life expectancy was 5.9 years (95%
CI 5.9–6.0) of which 4.8 (95% CI 4.0–5.7) were ULY.
Table 2 also shows the contribution of mortality differences
(‘mortality effect’) and disability differences (‘disability effect’) to
the gender difference in ULY. The lower mortality and higher
disability effect increased ULY in women relative to men. The con-
tribution of the mortality effect was 4.0 years and the disability effect
was 0.8 year.
Further decomposition of the mortality effect and disability effect
of ULY by cause is presented in table 3. Of the total mortality effect
of 4.0 ULYs, 1.8 ULYs were due to women’s lower mortality from
cancer, 0.8 ULY from heart disease and 0.3 ULY from accidents.
Table 3 also shows gender differences in the disability effects of
different diseases. Higher disability from musculoskeletal diseases
and anxiety-depression for women than men increased the gender
gap in ULY by 1.8 and 0.6 ULY, respectively. The gender gap in ULY
was reduced due to lower disability in women from: heart disease by
0.8 ULY, CNSLD by 0.4 ULY and accidents by 0.3 ULY. The sum of
the mortality and disability effects showed that musculoskeletal
diseases (due to their higher contribution of disability in women)
and cancer (due to their lower contribution of mortality in women)
had the greatest contribution to the longer ULY in women.
Discussion
Summary of findings
In our study, French women spend 4.8 more years with disability
than men, mainly because women live longer and are exposed to
disability in these additional years. This survival advantage in
women reflects their lower mortality from cancer and cardiovascular
diseases, and to a smaller extent accidents and respiratory diseases,
which together explained nearly 75% of women’s excess ULY. In
addition, a small disability effect, reflecting higher prevalence of
disability in women, contributed to <1 excess ULY in women.
This disability effect results from the opposing contributions of
specific conditions: musculoskeletal diseases and anxiety-
depression contributed more to disability in women than men;
and cardiovascular diseases, CNSLD and accidents contributed
more to disability in men.
Strengths and weaknesses
The strength of our study includes considering disparities in both
disability and mortality and using a very comprehensive and large
survey on disability and disease in the entire population. This study
used disability data by cause derived from a survey of people living
in private households and institutions and included a wide range of
conditions including the consequences of injuries and mental
diseases. We also had access to very detailed cause-of-death data,
which allowed us to make cause of death groups that best matched
with the diseases groups in the survey.
Table 3 Decomposition of gender differences (womenmen) in life expectancy with disability (ULY) at age 50, into mortality and disability
effects and total effect by cause, France 2008
Mortality effect (95% CI) Disability effect (95% CI) Total effect (95% CI)
Cardiovascular diseases
Heart disease 0.76 (0.75 to 0.77) 0.82 (1.37 to 0.27) 0.06 (0.60 to 0.49)
CVA 0.13 (0.13 to 0.14) 0.23 (0.45 to 0.00) 0.10 (0.31 to 0.13)
PVD 0.03 (0.03 to 0.03) 0.26 (0.48 to 0.07) 0.23 (0.44 to 0.03)
Other cardiovascular diseases 0.10 (0.10 to 0.10) n.a 0.10 (0.10 to 0.10)
Musculoskeletal diseases 0.00 (0.00 to 0.00) 1.84 (0.96 to 2.94) 1.84 (0.96 to 2.94)
Cancer 1.75 (1.74 to 1.77) 0.09 (0.23 to 0.43) 1.84 (1.54 to 2.18)
Neurological diseases
Alzheimer/Parkinson 0.04 (0.04 to 0.04) 0.08 (0.17 to 0.28) 0.12 (0.14 to 0.32)
Other neurological diseases 0.05 (0.04 to 0.05) 0.04 (0.22 to 0.12) 0.00 (0.17 to 0.17)
Respiratory diseases
CNSLD 0.14 (0.14 to 0.14) 0.41 (0.84 to 0.03) 0.27 (0.70 to 0.17)
Acute respiratory infections 0.10 (0.09 to 0.10) n.a 0.10 (0.09 to 0.10)
Mental diseases
Anxiety and depression 0.00 (0.00 to 0.00) 0.63 (0.20 to 1.04) 0.63 (0.20 to 1.04)
Other mental diseases 0.06 (0.06 to 0.07) 0.07 (0.22 to 0.03) 0.01 (0.01 to 0.02)
Diabetes mellitus 0.08 (0.07 to 0.08) 0.22 (0.15 to 0.59) 0.30 (0.07 to 0.66)
Accidents 0.28 (0.27 to 0.28) 0.32 (0.63 to 0.02) 0.05 (0.35 to 0.26)
Other/background 0.50 (0.48 to 0.51) 0.08 (0.27 to 0.33) 0.58 (0.22 to 0.83)
Total 4.0 (3.9 to 4.2) 0.8 (0.1 to 1.7) 4.8 (4.0 to 5.7)
Note: CVA = cerebrovascular accident (corresponding to cerebrovascular diseases according to the ICD-10 terminology). PVD = periphery
vascular diseases. CNSLD = chronic non-specific lung disease. n.a = not available, no separate cause of long-term disability. Gender differ-
ences in ULY can originate from higher disability and/or from lower mortality from the condition (extending the time at risk of disability
from any cause). The cause-specific mortality effects indicate the origin of the female excess in overall ULY resulting from lower female
mortality, although these diseases are not the causes of the ULY themselves. The total effect refers to the disease-specific origin of the
gender differences in ULY, either by higher (lower) disability from this condition, of by lower mortality from this condition, extending the
time at risk of disability from any conditions.
Table 2 Gender difference in ULYs at age 50, and the contribution
of mortality and disability differences for men and women, France,
2008
ULY
Years, (95% CI)
Men 14.2 (13.6 to 14.8)
Women 19.0 (18.4 to 19.6)
Difference
Womenmen 4.8 (4.0 to 5.7)
Contribution of mortality and disability differences
Mortality effect 4.0 (3.9 to 4.2)
Disability effect 0.8 (0.1 to 1.7)
Women’s excess unhealthy life years 3
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Some limitations of our study must be considered. First, data on
disability and diseases were self-reported. However, for most chronic
diseases, self-report is fairly accurate,24,25 with lowest accuracy for
arthritis.24,26 Moreover, there is no consistent evidence that men and
women form assessments of their health in different ways.27 Higher
disability prevalence in women was also found in several perform-
ance-based measures.28,29 Second, in contrast to the causes of death,
which are obtained from the death certificate, the causes of disability
in our study were based on a statistical attribution of disability to
diseases based on cross-sectional survey data. While this attribution
took into account competing causes of disability and the presence of
disability in people without any diseases, we cannot ascertain that all
diseases were present before the onset of disability. In particular for
depression, it cannot be ruled out that disability is the cause and not
the result of depression.30 Third, our data did not allow us to use a
cohort perspective nor to study changes over time. The Sullivan
method uses a period perspective which involves the stationary as-
sumptions,31 i.e. constant age-specific hazard rates and constant
births equal to the radix of the life table. Simulation studies have
shown that these assumptions have a minor influence on the results,
unless large changes have occurred in mortality and/or disability in
the study period.31–34 Therefore, the Sullivan method is routinely
used to calculate life expectancy with(out) disability. For the decom-
position method, based on the Sullivan method, it is noteworthy
that it identifies the extent to which differences in disability
prevalence and total mortality (in each age group) contribute to
ULY differences, but not the contribution of differences in
incidence of disability, recovery from disability and survival.1
Interpretation and comparison with prior studies
The decomposition analyses assessed which conditions contributed
to excess ULY in women. The focus was the origin of these differ-
ences and we took into account the excess ULY that can originate
from higher disability and/or from lower mortality from the
condition (extending the time at risk to disability from any cause).
The latter does not provide insight into the conditions that
contribute to the ULY resulting from the lower female mortality.
Women experience lower mortality, even after the advent of ill-
health,35 and explanations for this include biological (hormonal and
genetic), behavioral and social differences.25,29,36 It is plausible that
the same factors explain both lower mortality and lower disability
from cardiovascular diseases (e.g. hormonal, genetic, smoking,
alcohol consumption and diet), respiratory diseases (e.g. smoking)
and accidents (e.g. risk taking and alcohol consumption), supported
by the finding that the lower contribution of these conditions to
disability in women was due to lower disease prevalence since the
disabling impacts of these conditions did not differ by gender.9 Our
study found opposite contributions for musculoskeletal diseases,
diabetes and mental diseases. Compared to men, higher disability
in women from these conditions contributed to more ULY in
women. For musculoskeletal diseases and diabetes this reflected
both higher disease prevalence and higher disabling impact in
women than in men,9 perhaps due to higher frequency of obesity
and lower levels of physical activity in French women.37 Differences
in body composition (bone mass, muscle strength) and hormonal
differences may also have contributed to a higher susceptibility of
women to musculoskeletal diseases.38 The higher contribution of
mental diseases to disability in women than men mainly reflected
differences in disease prevalence.9 These gender differences in the
contribution of mental disease are widely acknowledged but less
understood.39
Similar to our study, prior decomposition analyses of gender dif-
ferences in life expectancy with disability1–3,6 showed a larger gender
gap in ULY than in HLY due to the combination of lower mortality
and higher disability, both extending ULY in women as compared to
men. Two previous studies looked at the contributions of diseases to
gender differences in life expectancy with disability.1,6 Our study
confirmed that arthritis contributed most to the longer life
expectancy with disability in women than in men because of the
disability effect while cancer was the main contributor to longer
ULY in women because of the mortality effect. However, the
earlier Dutch study1 showed no contribution from heart diseases
to the disability effect, while the Belgium study6 confirmed our
findings of a lower contribution of heart diseases to disability in
women for the year 2008, and additionally showed that this effect
changed over time from a higher contribution in 2001 for women
than for men, to a lower contribution in more recent periods. The
differences with the Dutch findings may also reflect differences in
timing of the study and the study population. The Dutch study1
used data from the early 1990s, and since then survival from heart
disease has increased substantially, persons who previously died
from the disease are now more likely to survive. In addition, the
Dutch study1 excluded the institutionalized population which may
explain the absence of the gender difference in the contribution of
heart disease.9
Prior research on the male–female health-survival paradox has
pointed to the role of different diseases: men are more likely to
die from fatal diseases and women suffer more from non-fatal
diseases.4,25,27,40 Our study confirmed that higher disability from
non-fatal diseases, such as musculoskeletal diseases and anxiety-
depression in women contributed to more ULYs in women, but
that this effect was partly nullified by higher prevalence of
disability in men from the traditional life-threatening diseases,
such as cardiovascular diseases, respiratory diseases and accidents.
A second explanation for the health-survival paradox given in the
literature is that women live longer and for that reason face more
disability.4 Our study confirmed that lower mortality tended to
increase ULY in women relative to men, and added that this
mortality effect was larger than the disability effect.
Conclusions, implications and recommendations
We find that both elements of the health-survival paradox, higher
disability and lower mortality, contribute to the excess ULYs in
French women compared to men, although women’s mortality
advantage was the main contributor. However, within the small
net contribution of the disability effect, diseases such as musculo-
skeletal diseases or anxiety-depression have a substantial positive
contribution, though this is offset by the negative contribution of
heart diseases, respiratory diseases and accidents. Diseases that are
traditionally seen as male fatal diseases also cause disability in men
and tend to reduce the gender gap in ULY.
Our study shows that diseases have a different impact on gender
differences in ULY, depending on whether the disease is mainly life-
threatening (such as cancer), mainly disabling (such as musculoskel-
etal) or both (such as heart diseases). A life-threatening disease
reduces ULY as people live shorter lives and therefore are less
exposed to disability from any cause. A disabling disease increases
ULY as persons experience disability from this disease. Whether a
disease which is both life-threatening and disabling reduces or
increases ULY depends on the relative size of both effects.
An implication of our findings for the strategy to reduce the
gender gap in ULY is that the largest reduction in the female disad-
vantage in ULY could be obtained by reducing male mortality dis-
advantage. However, this would not reduce ULY in women and
would increase ULY in men in the total population. Instead, there
is a strong need to target prevention of diseases that cause disability,
including musculoskeletal diseases which contribute most to
disability in both men and women. This includes policies and inter-
ventions that reduce obesity by targeting sedentary behavior,
physical inactivity and unhealthy diets. Moreover, reducing the
disabling consequences of diseases is increasingly important, as
people live longer with diseases that cause disability. Better disease
management, more use of assistive devices and technological devel-
opments and adaptation of the environment are examples to reduce
4 European Journal of Public Health
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the burden of disability in people with diseases. This may not only
reduce the gender gap in life expectancy with disability, but at the
same time avoid future increases in disability for both genders.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 French women’s disadvantage in ULYs compared to men is
predominantly due to women’s lower mortality from cancer,
cardiovascular and respiratory diseases and accidents.
 Women’s higher disability contributes moderately to their
excess ULYs.
 The substantial disabling effect of musculoskeletal diseases
in women’s ULY is offset by the lower contribution of heart
and respiratory diseases, and accidents compared to men.
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